ArticleIDCases2025
Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis and persistent bacteremia using adjunctive ceftaroline fosamil to vancomycin: A case report.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Comparison of Trough- and Online-Bayesian-Calculator-Derived AUCPharmaceuticals (Basel, Switzerland) · 2026Article
- Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of HumanAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ceftaroline fosamil is a novel cephalosporin antibiotic effective against methicillin-resistant Case report: We report a case of a 47-year-old male with a medical history of ischemic heart disease, heart failure with reduced ejection fraction, schizophrenia, hypertension, and type 2 diabetes mellitus who was admitted to the ICU with septic shock. Empiric treatment was initiated with meropenem and vancomycin. Vancomycin was given as 1000 mg IV every 24 h (18.8 mg/kg). Dosing was guided by serum vancomycin concentrations, with adjustments made by critical care clinical pharmacists to maintain target levels of 15-20 µg/mL (10-14 µmol/L). Over the following days, the patient was diagnosed with osteomyelitis, confirmed through CT and MRI imaging. Blood cultures subsequently grew MRSA. Despite 18 days of vancomycin therapy, he had persistent bacteremia, and the infectious disease team recommended the addition of ceftaroline fosamil to vancomycin to address the persistent bacteremia. Blood cultures turned negative within 24 h of initiating combination therapy. Conclusion: Ceftaroline fosamil shows promise as an adjunct therapy alongside vancomycin for treating osteomyelitis complicated by persistent bacteremia caused by MRSA. Further studies with a larger sample size are needed to refine its application in the management of MRSA osteomyelitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.